Neoadjuvant chemoimmunotherapy versus neoadjuvant chemoradiotherapy in patients with borderline resectable esophageal squamous cell carcinoma
NACI followed by surgery appears to be a safe and effective treatment strategy for patients with borderline resectable ESCC.
Authors
- Pengqiang Gao (ORCID: https://orcid.org/0000-0001-9692-8433)
- Hang Zhou (ORCID: https://orcid.org/0000-0003-1776-3736)
- Lin Zhou (ORCID: https://orcid.org/0000-0002-6428-7392)
- Hui‐Hui Lin (ORCID: https://orcid.org/0000-0002-3514-0391)
- Xiaofeng Chen (ORCID: https://orcid.org/0000-0002-0457-6854)
- Yujie Chen (ORCID: https://orcid.org/0000-0002-9905-9138)
- Weijie Chen (ORCID: https://orcid.org/0000-0002-9780-1167)
- Hao He (ORCID: https://orcid.org/0000-0001-7029-6992)
- Shuoyan Liu (ORCID: https://orcid.org/0000-0003-3749-1256)
- Peiyuan Wang
- Feng-Nian Zhuang
- Jun-Peng Lin
- Wenwei Wei
- Feng Wang (ORCID: https://orcid.org/0000-0003-3036-6735)
Institutions
- Fujian Medical University (CN)
- Fujian Provincial Cancer Hospital (CN)
- Putian University (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-08-16
- DOI
- https://doi.org/10.1186/s12967-025-06672-3
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Fujian Medical University